Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) (Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF), Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF)) has returned some encouraging pre-clinical results for its lead asset, OCT461201.
CEO John Lucas explains to Proactive London's Katie Pilbeam that it is estimated that 60% of cancer sufferers undergoing chemo are affected by CIPN at three months.
It was shown in animal models to reduce pain associated with chemotherapy-induced peripheral neuropathy (CIPN).
He says these latest results reaffirm the potential of OCT461201 across multiple indications.
The current market for the treatment of CIPN was valued at US$1.6bn in 2020 and is forecast to grow to US$2.37bn by 2027.